Inactive Instrument

Roche Holding AG Share Price Xetra

Equities

RHO

CH0012032113

Pharmaceuticals

Financials

Sales 2024 * 60.04B 65.73B 61.36B 5,255B Sales 2025 * 63.83B 69.88B 65.23B 5,587B Capitalization 178B 195B 182B 15,598B
Net income 2024 * 13.31B 14.57B 13.61B 1,165B Net income 2025 * 14.75B 16.15B 15.08B 1,291B EV / Sales 2024 * 3.21 x
Net Debt 2024 * 14.24B 15.59B 14.55B 1,246B Net Debt 2025 * 8.17B 8.94B 8.35B 715B EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
13 x
P/E ratio 2025 *
11.8 x
Employees 103,605
Yield 2024 *
4.4%
Yield 2025 *
4.55%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 31/12/02
Chairman 57 31/12/07
Director of Finance/CFO 57 31/03/11
Members of the board TitleAgeSince
Director/Board Member 72 02/03/15
Director/Board Member 59 -
Director/Board Member 65 31/12/95
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company